Hence, the aim of the present study was to investigate the prevalence of GA in advanced AMD and the proportion of eyes that would meet the indication criteria for treatment with the first upcoming intravitreal anti-C3 agent (pegcetacoplan). This evidence concerns the gene C3 and age-related macular degeneration.